Adage Capital Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Adage Capital Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-420,706	Closed	-$45.2M	–	981
2023 Q1	$45.2M	Sell	420,706 -681,133	-62%	-$78.4M	0.1%	235
2022 Q4	$121M	Sell	1,101,839 -63,161	-5%	-$4.1M	0.29%	81
2022 Q3	$68.7M	Buy	+1,165,000	New	+$53.3M	0.17%	141
2021 Q4	–	Sell	-347,315	Closed	-$8.23M	–	1128
2021 Q3	$8.23M	Sell	347,315 -27,685	-7%	-$653K	0.02%	752
2021 Q2	$9.21M	Sell	375,000 -100,000	-21%	-$2.23M	0.02%	720
2021 Q1	$8.67M	Buy	+475,000	New	+$9.81M	0.02%	719

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Adage Capital Partners's RXDX Position: Q2 2023 in Review

Adage Capital Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 420,706 shares — an estimated $45.2M sold.

Adage Capital Partners first reported a position in RXDX in Q1 2021 and held it in 6 quarters. The position peaked at $121M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Adage Capital Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Adage Capital Partners sold 420,706 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $45.2M.
Adage Capital Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Adage Capital Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $121M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.